
Pioneering AI-enhanced enzymes - exozymes - that can sustainably transform feedstock into nutraceuticals and medicines (Nasdaq: $EXOZ)
Los Angeles, CA
Joined February 2025
- Tweets222
- Following737
- Followers179
- Likes184
Have you booked your calendar? It's tomorrow that we're doing our quarterly investor update at 5PM ET / 2PM PT to discuss @eXoZymes results for the third quarter 2026. A press release detailing these results will be issued prior to the call.
Pre-register for the call here:
na2.hubs.ly/H091gW-0 $EXOZ
2
70
We're announcing our quarterly investor call on Thursday, November 19, 2026, at 5PM ET / 2PM PT to discuss @eXoZymes results for the third quarter 2026. A press release detailing these results will be issued prior to the call.
Investors can pre-register for the call here:
na2.hubs.ly/H08-y000 $EXOZ
Tomorrow Today show: AI, enzymes and the future of medicine - in a fascinating conversation on Tomorrow Today, @eXoZymes CEO Michael @Heltzen joins host @ShekharNat6833 to explore a future where biology becomes programmable, medicines are reimagined, and scientific breakthroughs move from the lab into the real world.
Go here to see more:
na2.hubs.ly/H08Njvn0
CEO @Heltzen discusses the road to commercialization in a fireside chat with @WTR_Research.
Key takeaway: With major manufacturing breakthroughs achieved and commercial-scale preparations underway, @eXoZymes is focused on bringing its first product to market - and proving the potential of its AI-enhanced biomanufacturing platform.
Watch the fireside chat - and access the report - here:
na2.hubs.ly/H08JY6d0 $EXOZ
The Next Industrial Revolution May Come From Biology: As biology shifts toward an engineering discipline, a Los Angeles biotech company, @eXoZymes (Nasdaq: $EXOZ), is betting that engineered enzyme systems can bridge the gap between digital molecule design and physical production.
Read the full @Benzinga feature here:
na2.hubs.ly/H08GTm10
Chief Commercial Officer at @eXoZymes, Damien @Perriman on the 'Balancing the Future' podcast:
"We think women's health is a really important frontier to move into. We're understanding a lot more about women's health today than we did before, and we're looking for materials that can make a real impact in that space. Mood, sleep, pain, these are all indications that we think are really important."
Full episode available here:
na2.hubs.ly/H08DsMq0 $EXOZ
From breakthrough science to commercial reality — what’s next for @eXoZymes?
Join CEO Michael @Heltzen tomorrow, October 22, at 11 AM ET / 8AM PT for a fireside chat with Robert Sassoon from @WTR_Research, covering commercialization, manufacturing economics, growth strategy, and key catalysts ahead.
🎟️ Free registration:
na2.hubs.ly/H08xGGD0 $EXOZ
AI is revolutionizing drug discovery. But there’s a billion-dollar problem nobody talks about: Making what AI discovers. As artificial intelligence unlocks an entirely new world of molecules and potential medicines, traditional manufacturing may struggle to keep pace.
In this @mashable feature, discover how @eXoZymes is working to bridge the gap between AI-powered discovery and real-world production - potentially changing how tomorrow’s medicines are made.
Full story on Mashable:
na2.hubs.ly/H08sRfL0 $EXOZ
CEO @heltzen on unlocking new medicinal chemistry space:
"By being able to do the double dip - nutraceuticals and pharmaceuticals - we can make sure that we invest our money and our time into something that does come to market, that does start making a difference, and that can frankly also help finance the journey on the pharmaceutical side, that everything equal is often where the biggest impact ends up happening, because we can customize the molecules for specific indications, aka diseases, and that way really make a difference in people's life."
If you didn't catch the recent episode of @eXoZymes being featured on @messaginglab's Grow Everything podcast, this is your chance:
na2.hubs.ly/H08hFWf0 $EXOZ
CEO @heltzen was recently interviewed by @PIX11News "Top Leaders" host, @TheNadjaAtwal
Michael Heltzen is leading @eXoZymes in rethinking biomanufacturing. By harnessing enzymes and AI, the company aims to produce health ingredients faster, sustainably, and closer to home—reducing reliance on traditional supply chains while making previously inaccessible natural compounds available at scale.
Full story available here:
na2.hubs.ly/H08gGW40 $EXOZ
Update from @Slack_Capital: What if @eXoZymes’ biggest opportunity isn’t a single molecule, but an AI-powered engine that combines computational design with cell-free biomanufacturing to repeatedly turn previously inaccessible chemistry into new products - and then do it all over again?
Read the full update from Slack Capital here:
na2.hubs.ly/H08fgX20 $EXOZ
CEO of @eXoZymes, Michael @heltzen, joins @messaginglab's 'Grow Everything' podcast to explain how cell-free biomanufacturing is opening new possibilities for natural products, nutraceuticals, and medicines.
“The only thing that will really, really stop that conversation about ‘can cell-free biomanufacturing really be true?’ is when people can pick a product off the shelf at their pharmacy and buy it for themselves. At that point, I think the conversation will finally - even for the most conservative segments - be over, that this is a new way of doing biomanufacturing without cells. It enables products that otherwise would be impossible or very difficult.”
Catch the entire episode right here:
na2.hubs.ly/H0895ZS0 $EXOZ
WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity
@WTR_Research’s new research report takes a close look at how @eXoZymes is moving from a promising scientific platform toward a potentially scalable commercial business.
7 things to know from the report:
* eXoZymes is moving from scientific validation toward commercial validation.
* NCT has emerged as the company’s key near-term commercial opportunity.
* The company has made significant progress in improving the economics of NCT production.
* Curia Global is now helping take the technology beyond pilot-scale production.
* The report sees substantial longer-term potential in pharmaceutical applications of the platform.
* Cannabinoids, santalene and five new molecules add further pipeline optionality.
* The next major milestones are scale-up, commercial partnerships and turning technical progress into revenue.
For investors looking to understand what has changed at $EXOZ, where the company is heading, and what needs to happen next, the report provides a timely look at the company’s evolving strategy and commercial opportunity.
Read the full report here - available with free login!
na2.hubs.ly/H088rNs0
eXoZymes retweeted
From pilot scale to commercial manufacturing: @eXoZymes has selected @CuriaCDMO to scale its cell-free NCT process in Spain and Italy. The Q4 2026 program will support a roadmap toward larger-scale production in 2027.
exozymes.com/blog/curia-nct-…
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
syntheticbiologysummit.com/?…
Next week, CEO @Heltzen, will be in New York around the annual @HCWCO investment conference. If you're also at the conference, feel free to schedule a meeting so we can meet up and get you updated on what's happening.
Additionally, if you're in town but not at the actual conference, let's explore the possibility to meet up elsewhere! Feel free to reach out to us through ir (at) exozymes (dot) com
Did you miss this? Last week, @Bio_Markets published a feature which positions @eXoZymes as an emerging leader in cell-free biomanufacturing, where removing living cells can accelerate production, improve process control, and lower costs. NCT is highlighted as a compelling example: a naturally scarce compound that $EXOZ can produce at commercial scale using its enzyme-based platform.
Full feature available here:
na2.hubs.ly/H07KKrz0 #NCT #exozymes #exozyme #enzymes #enzyme #biomanufacturing #cellfree
eXoZymes retweeted
Where synbio failed to commercialize, $EXOZ looks poised to deliver.
eXoZymes Selects @CuriaCDMO as Commercial-Scale Manufacturing Partner for NCT
Paul Opgenorth, PhD, VP of Development and co-founder of @eXoZymes, elaborates “We have demonstrated the NCT process at pilot scale and substantially improved its productivity and economics. Transferring our entire integrated process - from enzyme production through the cell-free NCT reaction to product purification - into a commercial manufacturing environment represents an important validation of its maturity. Having visited Curia’s facilities in both Spain and Italy, I’m confident we have selected a partner with the technical capabilities and infrastructure to take this next step with us.”
Read the full press release here:
na2.hubs.ly/H07Gv5Q0 $EXOZ
PharmaSource podcast: How $EXOZ Is Running a 10-CDMO RFP for CDMO Selection?
Damien @Perriman, Chief Commercial Officer at @eXoZymes: "We can adjust and be flexible around equipment configuration, but we can’t be flexible around what is a clear communicator and an honest partner."
In the latest @ThePharmaSource podcast episode, Perriman, explains how EXOZ is running its first major CDMO selection process for a platform unlike anything most contract manufacturers have run before, and why the company is weighing communication and cultural fit as heavily as technical capability.
Full episode available here:
na2.hubs.ly/H07JkL70
eXoZymes Selects @CuriaCDMO as Commercial-Scale Manufacturing Partner for NCT
Paul Opgenorth, PhD, VP of Development and co-founder of @eXoZymes, elaborates “We have demonstrated the NCT process at pilot scale and substantially improved its productivity and economics. Transferring our entire integrated process - from enzyme production through the cell-free NCT reaction to product purification - into a commercial manufacturing environment represents an important validation of its maturity. Having visited Curia’s facilities in both Spain and Italy, I’m confident we have selected a partner with the technical capabilities and infrastructure to take this next step with us.”
Read the full press release here:
na2.hubs.ly/H07Gv5Q0 $EXOZ
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheel
How @eXoZymes’ new strategy of retaining, de-risking and monetising high-value assets could create a self-reinforcing flywheel of value creation
The full research report from @Slack_Capital is freely available here:
na2.hubs.ly/H07t8HP0 $EXOZ


















